tbuckley/cabot-search huggingface dataset:
Phase II clinical trial with axitinib as maintenance therapy in patients (p) with metastatic colorectal carcinoma (CRC)
Authors: C. Gravalos, A. Carrato, M. Tobeña, E. Grande Pulido, G. Soler, J. Vieitez, L. Robles, M. Valladares-Ayerbes, E. Polo, M.L. Limon, M.J. Safont, C. Lopez, P. García Alfonso, E. Aranda
Journal: Annals of Oncology (2016)
Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma for Long-Term Follow-up: Single Center Results
Authors: Weiwei Sui, Dehui Zou, Gang An, Shuhui Deng, Yan Xu, Shuhua Yi, Zengjun Li, Yaozhong Zhao, Lugui Qiu
Journal: Blood (2016)
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer
Authors: E. Lattoni, C. Omarini, A.V. Tamma, S. Noventa, G. Orsi, F. Piacentini, L. Moscetti, S. Cascinu
Journal: Annals of Oncology (2016)
A Novel Regulatory Region of the p27 Locus Is Required for Normal Erythroid p27 Expression, and Produces a Long Noncoding RNA with No Detectable Function
Authors: Vikram R Paralkar, Cristian Taborda, Yu Yao, Rishi Prasad, Jing Luan, Ross C. Hardison, Gerd A. Blobel, Mitchell J Weiss
Journal: Blood (2015)
Evaluation of narrow-band imaging signs in eosinophilic and lymphocytic esophagitis
Authors: Tamaki Ichiya, Kyosuke Tanaka, Carlos Rubio, Ulf Hammar, Peter Schmidt
Journal: Endoscopy (2017)

<b>Background and study aims</b> No specific endoscopic signs for diagnosing eosinophilic esophagitis (EoE) have been described and very few studies have reported endoscopic signs for lymphocytic esophagitis (LyE). This study aimed to assess the utility of narrow-band imaging magnifying endoscopy (NBI-ME) in predicting EoE/LyE diagnosis before histopathological assessment. <b>Patients and methods</b> Adult patients with dysphagia and/or food impaction who underwent esophagogastroduodenoscopy followed by NBI-ME and biopsies were included. Three previously reported NBI-ME signs were studied: beige mucosa, dot-shaped intra-epithelial papillary capillary loop (IPCL), and absent cyan vessels. These signs were compared with the histological diagnosis, and studied in patients with and without EoE or LyE. A predictive model containing the NBI-ME signs was analyzed, based on area under the curve (AUC). <b>Results</b> A total of 137 patients were enrolled. Based on histology 26 were diagnosed with EoE, 26 with LyE, and 85 were control patients with neither diagnosis. Significantly more EoE/LyE patients than control patients showed the NBI signs (<i>P </i> < 0.001 for all three signs). Absent cyan vessels had the highest accuracy for differentiation (sensitivity 88 %, specificity 92 %). A combination of age, dot IPCLs, and absent cyan vessels was highly predictive of EoE/LyE, with an AUC of 0.952. <b>Conclusions</b> Three NBI-ME signs were found in the majority of patients with EoE/LyE and unlikely to be observed in controls. A combination of two NBI-ME signs and younger age had a higher degree of accuracy. This supports the claim that NBI-ME could be a reliable diagnostic modality for EoE/LyE predictors.
Allogeneic Cytokine-Induced Killer Cell-Dependent Eimination of Host Dendritic Cells Leads to Less Graft-Versus-Host Disease.
Authors: Shintaro Mase, Hideaki Maeba, Toshihiro Fujiki, Rie Kuroda, Raita Araki, Shoichi Koizumi, Akihiro Yachie, Ryosei Nishimura
Journal: Blood (2012)
BCR-ABL Kinase Domain Mutations in the P-Loop and at Imatinib Contact Sites in CML Patients with Imatinib Resistance Are Associated with Higher Maximum Imatinib Doses.
Authors: Oliver Pelz-Ackermann, Michael W.N. Deininger, Michael Cross, Kathrin Wildenberger, Rainer Krahl, Song-Yau Wang, Haifa K. Al-Ali, Dietger W. Niederwieser, Thoralf Lange
Journal: Blood (2007)
Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study
Authors: Daniel Aletaha, Clifton O Bingham, Yoshiya Tanaka, Prasheen Agarwal, Regina Kurrasch, Paul P Tak, Sharon Popik
Journal: The Lancet (2017)
Hypermethylation of DAP-K Is an Adverse Prognostic Factor in Patients with Multiple Myeloma (MM).
Authors: Esteban Braggio, Maria E. Gouveia, Roberto Magalhaes, Joao T. Souto, Marcia Garnica, Marcio Nucci, Angelo Maiolino, Ilana R. Zalcberg
Journal: Blood (2006)
STMC-18. ANATOMIC COMPARTMENTALIZATION OF CANCER STEM CELL SIGNATURES IN GLIOBLASTOMA
Authors: Ralph Puchalski, Nameeta Shah, Jeremy Miller, Charles Cobbs, Michael Hawrylycz
Journal: Neuro-Oncology (2016)

Cancer stem cells (CSCs) can be defined by functional attributes that include tumor initiation, persistent proliferation, and sustained self-renewal, but their gene signatures and specific anatomic contexts remain obscure. To characterize candidate signatures and explore specific locations in glioblastoma enriched for putative CSCs, we analyzed 270 transcriptomes of anatomic features and CSC profiles of the Ivy Glioblastoma Atlas (http://glioblastoma.alleninstitute.org/). The features included the leading edge, infiltrating tumor (transition zone between leading edge and cellular tumor), cellular tumor, pseudopalisading cells around necrosis, and microvascular proliferation, while the CSC profiles or clusters of putative CSCs were identified by RNA in situ hybridization analysis with probes to CD44, DANCR, HIF1A, ID1, ID2, IGFBP2, ITGA6, MET, MYC, NOS2, PDGFRA, PDPN, PI3, POSTN, PROM1, TGFBR2, or TNFAIP3. We found that histologically-distinct anatomic features exhibit highly conserved gene expression signatures across tumors despite intratumor and intertumor heterogeneity. These features provided a framework for defining three anatomic compartments enriched for putative CSC profiles on the basis of published CSC and cell type or phenotype signatures: a proliferative cellular tumor compartment, a blood vessel compartment, and a quiescent hypoxic compartment associated with immune cells. Compartmental organization of the CSC profiles is consistent with subtype-selective and anatomic feature-enriched gene expression.
Resourcing of Heparin and Low Molecular Weight Heparins from Bovine, Ovine, and Porcine Origin. Studies to Demonstrate the Biosimilarities
Authors: Debra Hoppensteadt, Paula Maia, Alice Silva, Emmanuel Kumar, Nil Guler, Walter Jeske, Daniel Kahn, Jeanine M. Walenga, Erwin Coyne, Jawed Fareed
Journal: Blood (2015)
Nucleophosmin Gene Mutations Identify a Favorable Risk Group in Childhood Acute Myeloid Leukemia with a Normal Karyotype.
Authors: Iris H. Hollink, Christian M. Zwaan, Marry M. van den Heuvel-Eibrink, Martin Zimmerman, Susan Arentsen-Peters, Rob Pieters, Jacqueline Cloos, Gertjan J. Kaspers, Siebold S. De Graaf, Ursula Creutzig, Dirk Reinhardt, Christian Thiede
Journal: Blood (2007)
The Neutrophil Alloantigen HNA-3a (5b) Is Encoded by an Amino Acid Substitution in Choline Transporter-Like Protein 2 (CTL2)
Authors: Brian R Curtis, Cox J Nancy, Mia J Sullivan, Anuar Konkashbaev, Krista Bowens, Kirk C Hansen, Richard H. Aster
Journal: Blood (2009)
STMC-12. Sox2 ACTIVATES THE EXPRESSION OF ONCO-miRNA-486-5p
Authors: Nicole Michelson, Hernando Lopez-Bertoni, Yunqing Li, John Laterra
Journal: Neuro-Oncology (2016)

Glioblastoma multiforme (GBM) and other solid malignancies are heterogeneous and contain subpopulations of tumor cells that exhibit stem-like features. These cancer stem cells (SCs) have the ability to self-renew and efficiently propagate tumor growth, and are thought to be a critical component of resistance to therapy. Recent findings from the Laterra lab point to a de-differentiation mechanism in which reprogramming transcription factors Oct4 and Sox2 drive non-SCs to express the stem-like phenotype in ­glioblastoma, in part by differentially regulating subsets of microRNAs (miRNAs). Currently, the molecular mechanisms by which reprogramming transcription factors and miRNAs coordinate SC tumor-propagating capacity are unclear. One commonly overlooked feature of reprogramming transcription factors (TFs) is their ability to inhibit gene transcription by acting on various downstream effectors. We postulate that these TFs drive tumorigenesis in part by activating miRNAs that target repressors of cell stemness and tumor propagating potential. In this study, we identify miRNA-486-5p as a Sox2-induced miRNA that regulates GBM SC self-renewal, through its inhibition of the tumor suppressor gene, FoxO1. Using established glioma cell lines and patient-derived neurospheres as models of GBM, we show that miR-486-5p associates with the GBM SC phenotype and is directly induced by Sox2. Forced expression of miR-486-5p in vitro enhances the self-renewal capacity of GBM neurospheres and inhibition of endogenous miR-486-5p leads to cell death, concomitant with the activation of the miRNA-486-5p target FoxO1. These results suggest that Sox2 regulates the survival of GBM stem cells, in part by activating miR-486-5p and repressing FoxO1, thereby preventing apoptosis of glioblastoma cells. The Sox2: miRNA-486-5p: FoxO1 axis offers a new target for therapies aiming to deplete GBM of its stem-like subset of cells responsible for malignancy and poor prognoses.
Application of Western patients-based Adjuvant! Online (AOL) model on Korean colon cancer patients.
Authors: M. Jung, G. Kim, J. Ahn, N. Kim, H. Chang, S. Y. Rha, H. C. Chung, J. K. Roh, S. Shin
Journal: Journal of Clinical Oncology (2011)

599 Background: Adjuvant! Online (AOL) is a web-accessible risk-assessment model that predicts the mortality and the benefits of adjuvant therapy ( www.adjuvantonline.org ). AOL has never been validated for Asian colon cancer patients. Methods: Using the Yonsei Tumor Registry (YTR) database, we calculated the survival for the patients with T1-4, N0-2, M0 colon cancer who were treated at the Yonsei Cancer Center between 1990 and 2005. Observed and predicted 5-year survival was compared for each patient. Results: The median age of the study population was 60 years (range, 15-87 years) and the median follow-up duration was 7.9 years (range, 0.06-19.8 years) for all 1,431 patients. While AOL underestimate overall survival (OS) (predicted-observed=-1.02%, P=0.008), it overestimate colon cancer-specific survival (CCSS) (predicted-observed=3.8%, P&lt;0.001) in Korean patients. Especially, AOL underestimated OS and CCSS in younger patients than age 50 years (predicted-observed=-4.3%, P&lt;0.001 and predicted-observed=-3.5%, P&lt;0.001, respectively). We conducted an internal model validation by using a Korean version of AOL (KAOL), which was a new model for prognosis based on AOL's parameters. 5-year OS and CCSS between the observed and the KAOL predicted survival were not different (77.25 vs. 77.15, P=0.873 and 77.4% vs. 77.6%, P=0.78, respectively). The concordance indexes about OS and CCSS were 0.75 and 0.74, respectively. Conclusions: KAOL model for Korean colon cancer patients is more suitable to predict 5-year outcomes compared to ALO model for Western patients. No significant financial relationships to disclose.
BMET-26. SURVIVAL AFTER SURGICAL RESECTION IN PATIENTS WITH SOLITARY OR MULTIPLE INTRACRANIAL METASTASES: RESULTS OF A SINGLE-CENTER RETROSPECTIVE STUDY
Authors: Nayan Lamba, Serena Faruque, Omar Arnaout, Timothy Smith
Journal: Neuro-Oncology (2016)

Brain metastases represent a significant source of illness and death in cancer patients, affecting 20-40% of all cancer patients and outnumbering primary brain cancers by 10 to 1. With recent improvements in targeted therapies, overall survival of cancer patients has improved, but has also led to an increasing incidence of brain metastases. It is therefore essential for neurosurgeons and oncologists to better understand how to optimally manage intracranial metastases. Several studies have demonstrated the utility of surgical resection in patients presenting with a solitary brain metastasis, and official guidelines published in 2010 recommend resection for solitary lesions. However, whether or not surgery provides benefit for patients with multiple brain metastases has been less definitive. Still, there have been several recent studies that have shown similar survival benefits in patients operated on for multiple metastases compared to those obtained for patients with solitary lesions. In this study, the authors compared overall survival after resection in patients with single and multiple intracranial lesions to better understand whether surgical resection should be recommended regardless of number of lesions at presentation. The authors retrospectively reviewed the records from a 37-year period at a single institution for patients with brain metastases treated via complete or partial resection of dominant lesions. There were 1700 patients identified. Of these, 297 had multiple surgeries performed and were therefore eliminated from the analysis. The cohort was then analyzed for overall survival. The Kaplan-Meier method (stratified by age, sex, primary tumor histology, and number of intracranial lesions prior to surgery) was used to calculate overall survival. A Cox proportional-hazards regression model was also fitted with the number of intracranial lesions as the predictor and survival as the outcome. Patient age, sex, and primary tumor histology were controlled for in each step of the analysis.
The Prognostic Significance of TP53 Mutations for Overall Outcome in Lower-Risk MDS Patients
Authors: Monika Belickova, Jitka Vesela, Anna Jonasova, Eliska Stara, Barbora Planetova, Zuzana Zemanova, Jana Brezinova, Dana Mikulenkova, Jaroslav Cermak
Journal: Blood (2014)
Causes of death statistics underestimate the burden of head and neck (H&amp;N) cancers: a nationwide study from France in 2008-2012 (EPICORL study)
Authors: C. Even, Y. Pointreau, L. Geoffrois, M. Schwarzinger, M. Bec, C. Godard, F. Huguet, S. Témam, S.P. Thiébaut
Journal: Annals of Oncology (2016)
Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC)
Authors: D. Cella, B. Escudier, N. Tannir, T. Powles, F. Donskov, K. Peltola, M. Schmidinger, D. Heng, P. Mainwaring, H. Hammers, J.-L. Lee, B.I. Rini, B. Roth, J. Baer, M. Mangeshkar, C. Scheffold, T. Hutson, S. Pal, R.J. Motzer, T.K. Choueiri
Journal: Annals of Oncology (2016)
Histone Deacetylase Inhibitor, PCI-24781, Induces Growth Inhibition and Apoptosis in Hematopoietic Tumor-Derived Cell Lines and Primary Leukemia Cells.
Authors: Joseph Buggy, Sriram Balasubramanian, Jason Ramos, Mint Sirisawad, Louie Naumovski
Journal: Blood (2006)
Altered Red Cell and Platelet Adhesion in the Hemolytic Diseases: Hereditary Spherocytosis, Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Anemia.
Authors: Andreia A. Canalli, Carla F. Franco-Penteado, Fabiola Traina, Nicola Conran, Rafael Morgante, Sheley Gambero, Sara T.O. Saad, Fernando F. Costa
Journal: Blood (2006)
Nursing experience and practice on Peripherally Inserted Central Catheters in adult cancer and not-cancer patients: A 7 year population-based analysis
Authors: B. Fai, M. Damin, L. Cason, P. Pocchetto Forato, F. Tagliapietra, G.M. Battistel, D. Pastorelli
Journal: Annals of Oncology (2016)
Prognostic role of pregnancy in breast cancer patients. a single institution experience
Authors: L. Diodati, B. Salvadori, E. Molinaro, I. Ferrarini, I. Bertolini, C. De Angelis, I. Montagnani, A. Aontana, E. Landucci, E. Pfanner, A. Michelotti, P. Ferrari, A. Falcone
Journal: Annals of Oncology (2016)
Related Nonmyeloablative Haploidentical (mini-haplo) Blood or Marrow Transplantation (BMT) with High-Dose Post-Transplant Cyclophosphmade (PTCy) for Acute Myeloid Leukemia (AML): Donor Age Impacts Outcome
Authors: Margaret M. Showel, Ephraim J. Fuchs, Ravi Varadhan, Mark J. Levis, Richard J. Jones
Journal: Blood (2015)
A case series of sporadic breast and ovarian cancers in Salentinian families with BRCA mutation-associated Hereditary Breast and Ovarian Cancer (HBOC) syndrome
Authors: E. De Matteis, M.R. De Giorgio, P. Tarantino, G. Ronzino, M. Ciccarese, L. Paolelli, R. Forcignanò, V.E. Chiuri, G. Cairo, L. Palma, S. Mauro, G. Surico
Journal: Annals of Oncology (2016)
Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
Authors: K. Weisel, A. Palumbo, A. Chanan-Khan, A.K. Nooka, I. Spicka, T. Masszi, M. Beksac, V. Hungria, M. Munder, M.-V. Mateos, T.M. Mark, A. Spencer, M. Qi, J. Schecter, H. Amin, X. Qin, W. Deraedt, T. Ahmadi, P. Sonneveld
Journal: Annals of Oncology (2016)
Retrospective Survey of Iron Overload Prevalence &amp; Chelation Practices in Transfusion-Dependent Myelodysplastic Syndromes in a West Kent District General Hospital, SE England.
Authors: Hajane Jeyabalasingam, Anil Vaikunth Kamat, Tariq Shafi, Raphael A. Ezekwesili
Journal: Blood (2009)
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstrom’s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.
Authors: Larry D. Anderson, Brenda M. Sandmaier, Michael B. Maris, Dietger Niederwieser, Edward Agura, Richard T. Maziarz, Thomas R. Chauncey, Rainer Storb, David G. Maloney
Journal: Blood (2006)
NCOG-15. A PROSPECTIVE STUDY OF HIPPOCAMPAL-SPARING PROPHYLACTIC CRANIAL IRRADIATION (PCI) IN LIMITED STAGE SMALL CELL LUNG CANCER (SCLC)
Authors: Kristin Redmond, Russell Hales
Journal: Neuro-Oncology (2016)

The purpose of this prospective study is to evaluate cognitive function, quality of life, and intra-cranial failure patterns following hippocampal (HC)-sparing PCI for limited stage SCLC. Adult patients with limited stage SCLC, with CR to concurrent chemo-radiotherapy and no brain metastases eligible. Patients received PCI 25 Gy/10 fractions with mean HC dose <8 Gy and ≥90% of brain receiving 90% of prescribed dose. Cognitive testing performed at baseline, 6, 12 months following RT. Brain MRIs performed at baseline, 6, 12, 18, 24 months. Primary endpoint was memory according to Hopkins Verbal Learning Test-Revised Delayed Recall (HVLT-R) at 6 months following PCI. The 25 Gy arm of RTOG 0212 using standard PCI was used as a reference. Development of intracranial metastases recorded. 20 patients with median age 61 years (range 39-76) enrolled. Two-year OS 88% (95% CI, 68-100%). No significant decline in performance between baseline and 6 or 12 months for any cognitive tests. Decline in performance on HVLT-R between baseline and 6 months was 0.38 compared to decline of 1 with standard PCI on RTOG 0212 (p=0.15, power 18% for 1-sided 0.05-level test with SD 3.6). MRI revealed asymptomatic brain metastases in 2 patients at 6 months and in 2 patients at 1 year (cumulative rate 20%) with no concurrent extra-cranial progression. Two patients (10%) developed a metastasis in under-dosed region. Neither involved HC dentate gyrus, but 1 involved the HC avoidance region (HC + 5 mm). Both patients concurrently developed ≥1 additional metastasis in fully treated brain regions. There was 1 neurologic death. This prospective study suggests a potential benefit of HC-sparing in limiting neuro-psychological sequelae of brain radiation, but with risk of failures in spared region. These data strongly support enrollment on NRG-CC003 which is accruing patients with both limited and extensive stage disease.
Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents
Authors: Efstathios Kastritis, Evangelos Terpos, Maria Gavriatopoulou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Marios Bakogeorgos, Despoina Kalapanida, Spyros Orfanopoulos, Vasiliki Bampali, Thaleia Meletiou, Dimitra Gika, Despoina Mparmparoussi, Charis Matsouka, Meletios A. Dimopoulos
Journal: Blood (2014)
PDCT-06. DIFFUSE INTRINSIC PONTINE GLIOMA AS A SECONDARY MALIGNANCY: A REPORT FROM THE DIPG REGISTRY AND REVIEW OF THE LITERATURE
Authors: Maia Anderson, Becky Zon, Daniel Polan, Martha Matuszak, Marcia Leonard, Daniel Spratt, Patricia Robertson, Carl Koschmann
Journal: Neuro-Oncology (2016)

Exposure to cranial radiation in childhood increases the risk of subsequent CNS malignancies, an important cause of late mortality. Studies have shown a linear relationship between radiation dose and risk of secondary meningiomas and gliomas. However no studies have specifically examined the development of diffuse intrinsic pontine glioma (DIPG) after childhood craniospinal radiation. Given the frequent brainstem irradiation and growing number of pediatric brain tumor survivors, we sought to investigate the risk of DIPG as a secondary malignancy in childhood cancer survivors. We performed a retrospective analysis of the DIPG Registry and Repository for cases of DIPG occurring after radiation therapy for primary pediatric CNS malignancies. We identified four cases of secondary DIPG confirmed by neuroimaging, three after primary medulloblastoma and one after ependymoma. Additionally, we performed an extensive literature search for secondary DIPG cases after radiation therapy for any primary childhood CNS malignancy. This search identified seven additional cases of brainstem glioma occurring after CNS radiation for primary medulloblastoma (n=5), pituitary macroadenoma (n=1), and pleomorphic xanthoastrocytoma (n=1). We were unable to confirm DIPG diagnosis by neuroimaging for these patients. For patients with available treatment and outcome data, DIPG occurred an average of 7.8 years (10.3 months-15 years) after completion of therapy. For patients with radiation details available, all received photon radiation to the brainstem (range 50-56.1 Gy) during primary tumor treatment. Patients died of disease an average of 6.5 months (4-10 months) after diagnosis. One patient has stable disease 13 months from diagnosis on adjuvant experimental treatment with panobinostat, a pan-HDAC inhibitor. In summary, secondary DIPG is a rare, but increasingly common, secondary malignancy in children who have received CNS radiation. A better understanding of the impact of radiation dose, field, and modality on the risk of secondary malignancies is necessary to guide future treatment of childhood CNS cancer.
Molecular Response After 3 Months of 1st Line Imatinib Therapy Is Predictive for Treatment Failure and Disease Progression In Patients with Chronic Phase Chronic Myeloid Leukemia - a Follow-up Analysis of the German CML Study IV
Authors: Benjamin Hanfstein, Martin C. Müller, Philipp Erben, Susanne Schnittger, Susanne Saussele, Armin Leitner, Ulrike Proetel, Gerhard Ehninger, Dieter K. Hossfeld, Hans-Jochem Kolb, Stefan W. Krause, Christoph Nerl, Hans Pralle, Dominik Heim, Gabriela M. Baerlocher, Hermann Heimpel, Rüdiger Hehlmann, Andreas Hochhaus
Journal: Blood (2010)